DOCSLIB.ORG

Changes in Serum TNF-Α, IL-18, and IL-6 Concentrations in Patients with Chronic Schizophrenia at Admission and at Discharge

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Changes in Serum TNF-Α, IL-18, and IL-6 Concentrations in Patients with Chronic Schizophrenia at Admission and at Discharge Comprehensive Psychiatry 90 (2019) 82–87 Contents lists available at ScienceDirect Comprehensive Psychiatry journal homepage: www.elsevier.com/locate/comppsych Changes in serum TNF-α, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge Yayan Luo 1,HongboHe1, Jie Zhang, Yufen Ou, Ni Fan ⁎ The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), 36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province 510370, China article info abstract Objective: Schizophrenia is correlated with aberrant cytokine concentrations. The goal of our study was to detect the serum concentrations of tumor necrosis factor (TNF)-α, interleukin (IL)-18, and IL-6 concentrations in patients with chronic schizophrenia in the acute relapse state at admission and at discharge and to analyze the correlations between the three cytokine concentrations with psychosis symptoms. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to analyze serum concentrations of TNF-α,IL-18, and IL-6 in 68 patients with chronic schizophrenia at admission and at discharge and in 80 controls. The Positive and Negative Syndrome Scale (PANSS) was used to analyze psychosis symptoms of the patients. Results: Serum concentrations of TNF-α, IL-18, and IL-6 in patients at admission were significantly elevated com- pared to those in controls. After treatment, IL-6 concentrations in patients at discharge were significantly reduced compared to those in patients at admission, and IL-6 concentrations showed no significant difference between patients at discharge and controls. In contrast, TNF-α and IL-18 concentrations showed no significant difference between patients at discharge and patients at admission, and TNF-α and IL-18 concentrations in patients at dis- charge were still significantly elevated compared to those in controls. IL-6 concentrations in patients at admission showed a positive correlation with negative scores, and IL-6 concentrations in patients at discharge showed positive correlations with positive, negative, and total scores. Reduction in IL-6 concentrations showed positive correlations with reduction in positive, negative, and total scores in patients at discharge. Conclusion: Serum concentrations of TNF-α, IL-18, and IL-6 were significantly elevated in patients with chronic schizophrenia in the acute relapse state.Aftertreatment,IL-6concentrations in patients at discharge were significantly reduced compared to these in patients at admission. © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1. Introduction as primary changed proinflammatory cytokines in patients with schizo- phrenia [5–9]. Schizophrenia (SZ) is a serious psychotic disease that occurs in nearly TNF-α, IL-18, and IL-6 are multifunctional proinflammatory cyto- 1% of the population worldwide [1]. Schizophrenia is manifested as dis- kines that are secreted primarily through monocytes and macrophages. turbed thinking, perception, belief, language, and social activities that These three cytokines play key roles in moderating the complicated occur during late adolescence or early adulthood and persist throughout events implicated in immunity and inflammation. The key roles of the life of the affected individuals [2]. Immune system dysfunction has TNF-α, IL-18, and IL-6 in regulating the excitability transmission of been implicated in the pathogenesis of schizophrenia [3]. The inflamma- neuron cell and neurotransmitter metabolisms make them primary tory immune response regulated by cytokines may contribute to the psy- candidates for schizophrenia pathogenesis [10]. Patients with chronic chopathology of schizophrenia through multidimensional mechanisms schizophrenia exhibited elevated serum concentrations of IL-6, TNF-α, affecting neurodevelopment, synaptic plasticity, and neurotransmission sIL-2R, IL-1β, and IL-18 [6,11–17]. Previous studies have shown that [3,4]. In particular, increasing evidence has concentrated on the actions IL-6 was likely to be a state-associated marker, which was elevated of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and IL-18 during the acute exacerbation state and normalized after antipsychotic treatment. These findings suggested that IL-6 concentrations could be Abbreviations: ELISA, enzyme-linked immunosorbent assay; PANSS, Positive and influenced by treatment or disease state [6,9,18–20]. Moreover, IL-6 Negative Syndrome Scale; TNF-α, tumor necrosis factor-alpha; IL-6, interleukin 6; IL-18, concentrations were positively correlated with positive symptoms and interleukin-18; sIL-2R, soluble IL-2 receptor. negative symptoms in schizophrenia [21,22]. The reduction in IL-6 ⁎ Corresponding author at: The Affiliated Brain Hospital of Guangzhou Medical levels in patients with schizophrenia was associated with the alleviation University, 36 Mingxin Rd, Liwan District, Guangzhou, Guangdong 510370, China. E-mail address: [email protected] (N. Fan). of negative symptoms [23]. Furthermore, high IL-6 concentrations at 1 These authors contributed equally to this work. baseline were associated with therapy resistance and long duration of https://doi.org/10.1016/j.comppsych.2019.01.003 0010-440X/© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Y. Luo et al. / Comprehensive Psychiatry 90 (2019) 82–87 83 hospitalization [13,24]. Together, these results suggested that IL-6 may the blood samples at 4000 rpm for 15 min; the serum was then sepa- be implicated in the response of the patient to antipsychotic therapy rated and stored at −80 °C before use. and could be regarded as a potential marker of cure response in schizo- Serum TNF-α, IL-18, and IL-6 concentrations were tested using phrenia. In contrast, TNF-α was likely to be considered as a trait marker, eBioscience ELISA kits (catalog numbers: BMS223, BMS213, and which shows no significant alterations after antipsychotic treatment BMS267, respectively, eBioscience, San Diego, USA). The sensitivities [9,19,20]. Compared with the more frequently analyzed cytokines, the were 0.13 pg/mL for TNF-α, 0.03 pg/mL for IL-6, and 9 pg/mL for IL- reports on the effect of antipsychotics on IL-18 are limited. A previous 18. The range of the standard curves varied from 0.31 to 20 pg/mL for study indicated that IL-18 exhibited a positive correlation with general TNF-α, from 0.09 to 5 pg/mL for IL-6, and from 19.5 to 1250 pg/mL for psychopathology of patients with chronic schizophrenia, but anti- IL-18. Duplicate tests were performed for standards and samples. Absor- psychotics have no effects on IL-18 concentrations [17]. bance at 450 nm was measured using a microplate reader. In the present study, the serum cytokine concentrations of TNF-α, IL-18, and IL-6 and psychosis symptoms of patients with schizophrenia 2.3. Data analysis were assessed during the first week of admission as baseline and in the week before the discharge. The aims of our study were to assess the All data were analyzed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). following in patients with chronic schizophrenia in the acute relapse The difference in gender between patients and healthy subjects was state: (1) the serum levels of inflammatory cytokines TNF-α, IL-18, determined by the chi-square test. The difference in age between pa- and IL-6 at admission and at discharge; (2) the correlation of inflamma- tients and healthy subjects was determined using independent t-test. tory cytokine concentrations at admission with the duration of admis- The difference of cytokine concentrations between patients at admis- sion; (3) the correlation of the cytokine levels at admission and at sion and patients at discharge was evaluated by the paired t-test. The discharge with the severity of the psychotic symptoms; and (4) the difference of cytokine concentrations between healthy subjects and association of the changes in these cytokine concentrations with the patients at admission or at discharge was evaluated by a covariance alleviations of psychotic symptoms. analysis with age and gender as covariates. Pearson's correlation analy- sis was performed to determine the correlation between cytokine con- 2. Methods centrations with demographic and clinical characteristics in patients with schizophrenia. Further multiple linear regression analysis was 2.1. Subjects applied to detect the correlation between cytokine concentrations with demographic and clinical characteristics in patients with schizo- Sixty-eight inpatients with chronic schizophrenia in the acute relapse phrenia. All of the presented variables from Table 1 were included in re- state were recruited from the Affiliated Brain Hospital of Guangzhou gression models. Categorical variables were converted into dummy Medical University as described in previous studies [6,9,13]. The inclusion variables in regression models. Multiple comparisons were corrected criteria for all patients were as follows: (1) diagnosed as schizophrenia on by Bonferroni's corrections [26]. p b 0.05 was considered significant. the basis of International Classification of Diseases-tenth edition (ICD-10) diagnostic criteria; (2) free of currently occurring allergies, autoimmune 3. Results disorders, and infections; (3) free of immunosuppressive or anti- inflammatory agent use; and (4) free of past history of substance use. 3.1. Clinical characteristics The diagnosis of these
Load more

Recommended publications
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Current Biological Treatments of Schizophrenia
    Schizophrenia Block Adapted from the American Society for Clinical Psychopharmacology Model Curriculum * Learning Objectives • Identify major target symptoms of schizophrenia treatment • Become familiar with conventional & atypical antipsychotic medications • Recognize major side effects of antipsychotic medications • Recognize unique features of clozapine & depot antipsychotics Outline • Background about Schizophrenia • Dopamine Hypothesis • Dopamine Pathways • Efficacy of Anti-psychotics • Treats agitation • Prevents relapse • Compliance, Medication dose & relapse • Overview of an Antipsychotic Medication Trial • Different Anti-psychotic medications • Side effects of the Anti-psychotics • Common-EPS, TD, anti-cholinergic, metabolic syndrome, • Rare but serious-NMS • Antipsychotic selection and treatment strategies algorithm Dopamine Hypothesis of Schizophrenia Dopamine Hypothesis • Psychotic symptoms can be induced by dopamine agonists* • cocaine, amphetamines cause psychosis • All anti-psychotics are dopamine antagonists • Normal subjects-10% dopamine receptors occupied at baseline** • Schizophrenic subjects-20% dopamine receptors occupied at baseline** **Laruelle M, Quart J Nuc Med 1998;42:211 * Major Dopamine Pathways 1. Nigrostriatal tract- (extrapyramidal pathway) substantia nigra to caudate nucleus & putamen of the basal ganglia 2. Mesolimbic tract - midbrain tegmentum to nucleus accumbens & adjacent limbic structures 3. Mesocortical tract - midbrain tegmentum to anterior cortical areas 4. Tuberoinfundibular tract - arcuate &
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Antipsychotics (Part-4) FLUOROBUTYROPHENONES
    Antipsychotics (Part-4) FLUOROBUTYROPHENONES The fluorobutyrophenones belong to a much-studied class of compounds, with many compounds possessing high antipsychotic activity. They were obtained by structure variation of the analgesic drug meperidine by substitution of the N-methyl by butyrophenone moiety to produce the butyrophenone analogue which has similar activity as chlorpromazine. COOC2H5 N H3C Meperidine COOC2H5 N O Butyrophenone analog The structural requirements for antipsychotic activity in the group are well worked out. General features are expressed in the following structure. F AR Y O N • Optimal activity is seen when with an aromatic with p-fluoro substituent • When CO is attached with p-fluoroaryl gives optimal activity is seen, although other groups, C(H)OH and aryl, also give good activity. • When 3 carbons distance separates the CO from cyclic N gives optimal activity. • The aliphatic amino nitrogen is required, and highest activity is seen when it is incorporated into a cyclic form. • AR is an aromatic ring and is needed. It should be attached directly to the 4-position or occasionally separated from it by one intervening atom. • The Y group can vary and assist activity. An example is the hydroxyl group of haloperidol. The empirical SARs suggest that the 4-aryl piperidino moiety is superimposable on the 2-- phenylethylamino moiety of dopamine and, accordingly, could promote affinity for D2 receptors. The long N-alkyl substituent could help promote affinity and produce antagonistic activity. Some members of the class are extremely potent antipsychotic agents and D2 receptor antagonists. The EPS are extremely marked in some members of this class, which may, in part, be due to a potent DA block in the striatum and almost no compensatory striatal anticholinergic block.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al
    USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/00398.69 A1 Wermeling Et Al
    US 200600398.69A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/00398.69 A1 Wermeling et al. (43) Pub. Date: Feb. 23, 2006 (54) INTRANASAL DELIVERY OF Publication Classification ANTIPSYCHOTC DRUGS (51) Int. Cl. A6IK 9/14 (2006.01) A61 K 3/445 (2006.01) A6IL 9/04 (2006.01) (76) Inventors: Daniel Wermeling, Lexington, KY (52) U.S. Cl. .............................................. 424/46; 514/317 (US); Jodi Miller, Acworth, GA (US) (57) ABSTRACT An intranasal drug product is provided including an antip Correspondence Address: Sychotic drug, Such as haloperidol, in Sprayable Solution in MAYER, BROWN, ROWE & MAW LLP an intranasal metered dose Sprayer. Also provided is a P.O. BOX2828 method of administering an antipsychotic drug, Such as CHICAGO, IL 60690-2828 (US) haloperidol, to a patient, including the Step of delivering an effective amount of the antipsychotic drug to a patient intranasally using an intranasal metered dose Sprayer. A (21) Appl. No.: 10/920,153 method of treating a psychotic episode also is provided, the method including the Step of delivering an antipsychotic drug, Such as haloperidol, intranasally in an amount effective (22) Filed: Aug. 17, 2004 to control the psychotic episode. Patent Application Publication Feb. 23, 2006 US 2006/00398.69 A1 30 525 2 20 -- Treatment A (M) S 15 - Treatment B (IM) 10 -- Treatment C (IN) i 2 O 1 2 3 4 5 6 Time Post-dose (hours) F.G. 1 US 2006/0039869 A1 Feb. 23, 2006 INTRANASAL DELIVERY OF ANTIPSYCHOTC therefore the dosage form of choice in acute situations. In DRUGS addition, the oral Solution cannot be "cheeked' by patients.
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]
  • Placebo Response in Antipsychotic Clinical Trials a Meta-Analysis
    Research Original Investigation | META-ANALYSIS Placebo Response in Antipsychotic Clinical Trials A Meta-analysis Bret R. Rutherford, MD; Emily Pott, BA; Jane M. Tandler, BA; Melanie M. Wall, PhD; Steven P. Roose, MD; Jeffrey A. Lieberman, MD Supplemental content at IMPORTANCE Because increasing placebo response rates decrease drug-placebo differences jamapsychiatry.com and increase the number of failed trials, it is imperative to determine what is causing this trend. OBJECTIVES To investigate the relationship between antipsychotic medication and placebo response by publication year, and to identify associated study design and implementation variables. DATA SOURCES MEDLINE, PsycINFO, and PubMed were searched to identify randomized clinical trials of antipsychotic medications published from 1960 to July 2013. STUDY SELECTION Included were randomized clinical trials lasting 4 to 24 weeks, contrasting antipsychotic medication with placebo or an active comparator, and enrolling patients 18 years of age or older with schizophrenia or schizoaffective disorder. DATA EXTRACTION AND SYNTHESIS Standardized mean change scores were calculated for each treatment arm, plotted against publication year, and tested with Spearman rank correlation coefficients. Hierarchical linear modeling identified factors associated with the standardized mean change across medication and placebo treatment arms. MAIN OUTCOMES AND MEASURES We hypothesized that the mean change in placebo-treated patients would significantly increase from 1960 to the present, that a greater change would be observed in active comparator vs placebo-controlled trials, and that more protocol visits would increase the symptom change observed. RESULTS In the 105 trials examined, the mean change observed in placebo arms increased significantly with year of publication (n = 39, r = 0.52, P = .001), while the mean change in effective dose medication arms decreased significantly (n = 208, r =−0.26,P < .001).
    [Show full text]
  • Antipsychotics-Children-Surveillance
    AHRQ Comparative Effectiveness Review Surveillance Program CER #39: First & second generation antipsychotics for children and young adults Original Release Date: February, 2012 Surveillance Report: November, 2012 Surveillance Report: October, 2014 Summary of Key Findings from Surveillance Reports: • For Key Question 1, studies were identified suggesting that conclusions related to the effectiveness of Second Generation Antidepressants (SGA) for anorexia nervosa are out of date, that conclusions related to the comparative effectiveness of First Generation Antidepressants (FGA) and SGAs are possibly out of date, that the conclusion of no difference between SGAs and placebo for aggression is possibly out of date, that the strength of evidence (SOE) for SGAs and improvement on mania scales may possibly increase from low to moderate, and the SOE regarding risperidone and reduction in problem behavior may have increased. • For Key Question 2, conclusions related to cardiovascular events and weight gain, and the tolerability of molidone hydrochloride are possibly out of date, and the SOE for additional adverse events may possibly increase from moderate to high. • For Key Question 3, the conclusion on the safety and tolerability of FGAs vs. SGAs is possibly out of date. • For Key Question 4, conclusions related to individuals with comorbid disorders are possibly out of date. Signal Assessment: The signals examined in this surveillance assessment suggest that the original CER is possibly out of date. i Authors: Karli Kondo Maya O’Neil Shammarie Mathis Ryan McKenna Kelly Vander Ley Johanna Anderson Mark Helfand Conflict of Interest: None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
    [Show full text]
  • Haloperidol Injection, Usp
    PRODUCT MONOGRAPH Pr HALOPERIDOL INJECTION, USP 5 mg/mL 1 mL and 10 mL ‒ multiple-dose vials Contains Preservatives For intramuscular injection only. ANTIPSYCHOTIC AGENT Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 September 12, 2016 Toronto, ON M9W 0C8 Submission Control No.: 197951 PrHaloperidol Injection, USP 5 mg/mL, 1 mL and 10 mL Vials THERAPEUTIC CLASSIFICATION Antipsychotic Agent ACTION AND CLINICAL PHARMACOLOGY Haloperidol injection (intramuscular) is a butyrophenone derivative with antipsychotic properties that has been considered particularly effective in the management of hyperactivity, agitation and mania. Haloperidol is an effective neuroleptic and also possesses antiemetic properties; it has a marked tendency to provoke extrapyramidal effects and has relatively weak alpha-adrenolytic properties. It may also exhibit hypothermic and anorexiant effects, and potentiate the action of barbiturates, general anesthetics, and other CNS depressant drugs. As with other neuroleptics, the mechanism of action of haloperidol has not been clearly established, but it has been shown to be a dopamine receptor antagonist. Peak plasma levels of haloperidol occur within about twenty minutes after intramuscular administration. Protein binding is 90% or more. Haloperidol is extensively metabolized by the liver and the metabolites are subsequently excreted in the urine and feces, via the bile. The half- life of elimination is 21 hours (range 13 to 35 hours). INDICATIONS AND CLINICAL USE Haloperidol Injection, USP (intramuscular) is indicated for the rapid control of the acute manifestations of schizophrenia and manic states. It may also be of value in the management of aggressive and agitated behaviour in patients with chronic brain syndrome and mental retardation and in the symptomatic control of Gilles de la Tourette’s syndrome.
    [Show full text]
  • Electronic Search Strategies
    Appendix 1: electronic search strategies The following search strategy will be applied in PubMed: ("Antipsychotic Agents"[Mesh] OR acepromazine OR acetophenazine OR amisulpride OR aripiprazole OR asenapine OR benperidol OR bromperidol OR butaperazine OR Chlorpromazine OR chlorproethazine OR chlorprothixene OR clopenthixol OR clotiapine OR clozapine OR cyamemazine OR dixyrazine OR droperidol OR fluanisone OR flupentixol OR fluphenazine OR fluspirilene OR haloperidol OR iloperidone OR levomepromazine OR levosulpiride OR loxapine OR lurasidone OR melperone OR mesoridazine OR molindone OR moperone OR mosapramine OR olanzapine OR oxypertine OR paliperidone OR penfluridol OR perazine OR periciazine OR perphenazine OR pimozide OR pipamperone OR pipotiazine OR prochlorperazine OR promazine OR prothipendyl OR quetiapine OR remoxipride OR risperidone OR sertindole OR sulpiride OR sultopride OR tiapride OR thiopropazate OR thioproperazine OR thioridazine OR tiotixene OR trifluoperazine OR trifluperidol OR triflupromazine OR veralipride OR ziprasidone OR zotepine OR zuclopenthixol ) AND ("Randomized Controlled Trial"[ptyp] OR "Controlled Clinical Trial"[ptyp] OR "Multicenter Study"[ptyp] OR "randomized"[tiab] OR "randomised"[tiab] OR "placebo"[tiab] OR "randomly"[tiab] OR "trial"[tiab] OR controlled[ti] OR randomized controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR single-blind method[mh] OR "Clinical Trial"[Ptyp] OR "Clinical Trials as Topic"[Mesh]) AND (((Schizo*[tiab] OR Psychosis[tiab] OR psychoses[tiab] OR psychotic[tiab] OR disturbed[tiab] OR paranoid[tiab] OR paranoia[tiab]) AND ((Child*[ti] OR Paediatric[ti] OR Pediatric[ti] OR Juvenile[ti] OR Youth[ti] OR Young[ti] OR Adolesc*[ti] OR Teenage*[ti] OR early*[ti] OR kids[ti] OR infant*[ti] OR toddler*[ti] OR boys[ti] OR girls[ti] OR "Child"[Mesh]) OR "Infant"[Mesh])) OR ("Schizophrenia, Childhood"[Mesh])).
    [Show full text]